We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Consensus Estimate for revenues is pegged at $3.65 billion, while the same for earnings is pinned at $0.63 per share.
Factors to Consider
The company reports under four segments on the basis of geography — Developed Markets; Emerging Markets; Japan, Australia and New Zealand (“JANZ”); and Greater China.
Growth in Developed Markets driven by brands has likely boosted sales from this segment and offset the decline in the generics business.
While brands' sales from Europe, led by EpiPen, Creon and Brufen, have likely maintained growth, the same from North America have possibly been under pressure due to an import alert for the manufacturing facility in Indore, India, and competition for Wixela and other products.
Following an inspection of Viatris' oral finished dose manufacturing facility in Indore, India, in June 2024, the company received a warning letter and import alert from the FDA in December 2024. The import alert affects 11 actively distributed products, including lenalidomide and everolimus.
The Zacks Consensus Estimate for revenues from Developed Markets is pinned at $2.2 billion.
Sales from Emerging Markets have likely experienced growth driven by strength in Turkey and development in the Asia region. Stabilization in the Korean markets also positively impacted sales in the second quarter, a trend that most likely prevailed in the third quarter as well.
The Zacks Consensus Estimate for revenues from this geography is pegged at $550 million.
Sales in JANZ are likely to have been adversely impacted by government price regulations and a change in reimbursement policy impacting off-patent brands in Japan and competition in Australia.
The Zacks Consensus Estimate for revenues from the JANZ markets is pinned at $303 million.
Sales in Greater China might have seen an increase due to the company’s diversified model.
The Zacks Consensus Estimate for revenues from this geography is pegged at $579 million.
Viatris also reports revenues under two divisions (in terms of product category) — brands and generics.
Brand business comprises the majority of the company’s portfolio. Brand performance is likely to have benefited from strong performance in Greater China and Emerging Markets, in addition to growth in certain key brands in Developed Markets. However, the generics business has likely been negatively impacted by inspection at the Indore facility and competition for Wixela, partially offset by continued growth in Yupelri and Breyna in North America, strong performance across key European markets, and slight volume growth in JANZ.
Operating expenses declined in the second quarter on a sequential basis as a result of the planned cost-saving initiatives. The trend has most likely continued in the third quarter.
VTRS’ Share Price Performance
Viatris’ shares have lost 16.8% year to date against the industry’s gain of 2.5%.
Image Source: Zacks Investment Research
VTRS’ Mixed Earnings Surprise History
The company’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, delivering an average surprise of 4.45%. In the last reported quarter, VTRS beat on earnings by 10.71%.
Our proven model predicts an earnings beat for VTRS this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. This is the case here, as you will see below.
Earnings ESP: VTRS has an Earnings ESP of +0.53%. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #2.
Other Stocks to Consider
Here are some other drug/biotech stocks that, too, have the right combination of elements to beat on earnings this time around.
ZYME is scheduled to report third-quarter earnings on Nov. 6, 2025. The stock has gained 30.4% so far this year. ZYME beat on earnings in each of the trailing four quarters, delivering an average surprise of 36.18%.
Nektar Therapeutics (NKTR - Free Report) has an Earnings ESP of +18.72% and a Zacks Rank #2 at present. NKTR is scheduled to report third-quarter earnings on Nov. 6, 2025. Nektar shares have skyrocketed 365.7% so far this year.
ANI Pharmaceuticals (ANIP - Free Report) has an Earnings ESP of +10.55% and a Zacks Rank #2 at present. ANIP is scheduled to report third-quarter earnings on Nov. 7, 2025.
ANIP beat on earnings in each of the trailing four quarters, delivering an average surprise of 22.66%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Viatris to Report Q3 Earnings: Is a Beat in the Cards for the Stock?
Key Takeaways
Viatris (VTRS - Free Report) , a global healthcare company, is scheduled to report third-quarter 2025 results on Nov. 6, 2025, before the bell.
The Zacks Consensus Estimate for revenues is pegged at $3.65 billion, while the same for earnings is pinned at $0.63 per share.
Factors to Consider
The company reports under four segments on the basis of geography — Developed Markets; Emerging Markets; Japan, Australia and New Zealand (“JANZ”); and Greater China.
Growth in Developed Markets driven by brands has likely boosted sales from this segment and offset the decline in the generics business.
While brands' sales from Europe, led by EpiPen, Creon and Brufen, have likely maintained growth, the same from North America have possibly been under pressure due to an import alert for the manufacturing facility in Indore, India, and competition for Wixela and other products.
Following an inspection of Viatris' oral finished dose manufacturing facility in Indore, India, in June 2024, the company received a warning letter and import alert from the FDA in December 2024. The import alert affects 11 actively distributed products, including lenalidomide and everolimus.
The Zacks Consensus Estimate for revenues from Developed Markets is pinned at $2.2 billion.
Sales from Emerging Markets have likely experienced growth driven by strength in Turkey and development in the Asia region. Stabilization in the Korean markets also positively impacted sales in the second quarter, a trend that most likely prevailed in the third quarter as well.
The Zacks Consensus Estimate for revenues from this geography is pegged at $550 million.
Sales in JANZ are likely to have been adversely impacted by government price regulations and a change in reimbursement policy impacting off-patent brands in Japan and competition in Australia.
The Zacks Consensus Estimate for revenues from the JANZ markets is pinned at $303 million.
Sales in Greater China might have seen an increase due to the company’s diversified model.
The Zacks Consensus Estimate for revenues from this geography is pegged at $579 million.
Viatris also reports revenues under two divisions (in terms of product category) — brands and generics.
Brand business comprises the majority of the company’s portfolio. Brand performance is likely to have benefited from strong performance in Greater China and Emerging Markets, in addition to growth in certain key brands in Developed Markets. However, the generics business has likely been negatively impacted by inspection at the Indore facility and competition for Wixela, partially offset by continued growth in Yupelri and Breyna in North America, strong performance across key European markets, and slight volume growth in JANZ.
Operating expenses declined in the second quarter on a sequential basis as a result of the planned cost-saving initiatives. The trend has most likely continued in the third quarter.
VTRS’ Share Price Performance
Viatris’ shares have lost 16.8% year to date against the industry’s gain of 2.5%.
Image Source: Zacks Investment Research
VTRS’ Mixed Earnings Surprise History
The company’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, delivering an average surprise of 4.45%. In the last reported quarter, VTRS beat on earnings by 10.71%.
Viatris Inc. Price, Consensus and EPS Surprise
Viatris Inc. price-consensus-eps-surprise-chart | Viatris Inc. Quote
What Our Model Predicts for Viatris
Our proven model predicts an earnings beat for VTRS this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. This is the case here, as you will see below.
Earnings ESP: VTRS has an Earnings ESP of +0.53%. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #2.
Other Stocks to Consider
Here are some other drug/biotech stocks that, too, have the right combination of elements to beat on earnings this time around.
Zymeworks (ZYME - Free Report) has an Earnings ESP of +2.22% and a Zacks Rank #1 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
ZYME is scheduled to report third-quarter earnings on Nov. 6, 2025. The stock has gained 30.4% so far this year. ZYME beat on earnings in each of the trailing four quarters, delivering an average surprise of 36.18%.
Nektar Therapeutics (NKTR - Free Report) has an Earnings ESP of +18.72% and a Zacks Rank #2 at present. NKTR is scheduled to report third-quarter earnings on Nov. 6, 2025. Nektar shares have skyrocketed 365.7% so far this year.
ANI Pharmaceuticals (ANIP - Free Report) has an Earnings ESP of +10.55% and a Zacks Rank #2 at present. ANIP is scheduled to report third-quarter earnings on Nov. 7, 2025.
ANIP beat on earnings in each of the trailing four quarters, delivering an average surprise of 22.66%.